The Form 4 filing, an SEC report of insider stock activity, was filed on October 27, 2026. It lists October 26, 2026, as both the first and last transaction date. Martine A. Rothblatt serves as chairperson and CEO of United Therapeutics (UTHR).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-26 |
| Date of Latest Transaction | 2026-10-26 |
| Buy/Sell | sell |
| Transaction Count | 8 |
| Shares Transacted | 9,500 |
| Price | $588.64 |
| Total Transaction Value | $5,592,094.67 |
| Insider | |
| Ticker Symbol | UTHR |
| Company | UNITED THERAPEUTICS Corp |
| Insider Name | ROTHBLATT MARTINE A |
| Insider Title | Chairperson & CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 324,443 |
| Position Size Change | 2.84% |
| Filing | |
| Filing Date | 2026-10-27 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with transaction code S. One insider reported eight transactions totaling 9,500 UTHR shares in a single filing.
What was the average price of the transaction?
The average sale price was $588.64 per share, rounded to the nearest cent. Prices for the eight separate sales are not available.
How did this transaction affect the insider's holdings?
Martine A. Rothblatt sold 9,500 shares and reported 324,443 shares owned after the sales. The shares sold made up 2.84% of the shares held before the sales.
What's the total transaction value?
The total value was $5,592,094.67 across all eight sales. The more precise reported figure was $5,592,094.6672, which rounds to that amount in cents.
Are there any special circumstances around this transaction?
The filing information includes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The footnote text is unavailable, so it is unclear which of the eight sales the reference covers. The plan's start date and trading terms are also unknown.
For research purposes only; not investment advice.